» Articles » PMID: 38391718

Coexisting Biopsy-Diagnosed Dementia and Glioblastoma

Overview
Journal Brain Sci
Publisher MDPI
Date 2024 Feb 23
PMID 38391718
Authors
Affiliations
Soon will be listed here.
Abstract

Both glioblastoma (GBM) and dementia are devastating diseases with limited treatments that are usually not curative. Having clinically diagnosed dementia with an associated biopsy-proven etiology and a coexisting GBM diagnosis is a rare occurrence. The relationship between the development of neurodegenerative dementia and GBM is unclear, as there are conflicting reports in the literature. We present two cases of simultaneous biopsy-proven dementia, one with Alzheimer's disease (AD) and GBM, and one with cerebral amyloid angiopathy (CAA) and GBM. We discuss how these diseases may be associated. Whether one pathologic process begins first or develops concurrently is unknown, but certain molecular pathways of dementia and GBM appear directly related while others inversely related. Further investigations of these close molecular relationships between dementia and GBM could lead to development of improved diagnostic tools and therapeutic interventions for both diseases.

Citing Articles

Deciphering novel mitochondrial signatures: multi-omics analysis uncovers cross-disease markers and oligodendrocyte pathways in Alzheimer's disease and glioblastoma.

Xu X, Wang J, Chen T, Wang S, Wang F, He J Front Aging Neurosci. 2025; 17:1536142.

PMID: 40018519 PMC: 11865232. DOI: 10.3389/fnagi.2025.1536142.

References
1.
Sanchez-Valle J, Tejero H, Ibanez K, Portero J, Krallinger M, Al-Shahrour F . A molecular hypothesis to explain direct and inverse co-morbidities between Alzheimer's Disease, Glioblastoma and Lung cancer. Sci Rep. 2017; 7(1):4474. PMC: 5493619. DOI: 10.1038/s41598-017-04400-6. View

2.
Mattson M . Emerging neuroprotective strategies for Alzheimer's disease: dietary restriction, telomerase activation, and stem cell therapy. Exp Gerontol. 2000; 35(4):489-502. DOI: 10.1016/s0531-5565(00)00115-7. View

3.
Batchelor T, Mulholland P, Neyns B, Nabors L, Campone M, Wick A . Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013; 31(26):3212-8. PMC: 4021043. DOI: 10.1200/JCO.2012.47.2464. View

4.
Kim Y, Jeong B . Identification of Somatic Mutations in Dementia-related Genes in Cancer Patients. Curr Alzheimer Res. 2020; 17(9):835-844. DOI: 10.2174/1567205017666201203124341. View

5.
Fowler J . 21 years of biologically effective dose. Br J Radiol. 2010; 83(991):554-68. PMC: 3473681. DOI: 10.1259/bjr/31372149. View